Important to pick a good long entry level as this one can be volatile.
Not a recommendation
Possible stop below C or last pivot low.
ARK ETF Trust - ARK Genomic Revolution ETF is an exchange traded fund launched and managed by ARK Investment Management LLC. It invests in public equity markets of global region. The fund invests in stocks of companies operating across diversified sectors. It invests in growth and value stocks of companies across diversified market capitalization. The fund invests in stocks of companies that are deemed socially conscious in their business dealings and directly promote environmental responsibility. The fund employs fundamental and quantitative analysis with bottom-up and top-down stock picking approach to create its portfolio. It benchmarks the performance of its portfolio against the S&P 500 Index and the MSCI World Index. The fund employs internal and external research to create its portfolio. ARK ETF Trust - ARK Genomic Revolution ETF was formed on October 31, 2014 and is domiciled in the United States.
The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified. Benchmark: NASDAQ Health Care GR EUR.
Holdings are an important aspect of an ETF for most. ETFs can be in the same sector yet still have almost totally different holdings at times.
Biotech has pulled back a lot, but biotech is also volatile as a rule.
Top 10 Holdings
Teladoc Health Inc
7.07%
Pacific Biosciences of California Inc
5.24%
Exact Sciences Corp
4.87%
Twist Bioscience Corp
4.55%
Regeneron Pharmaceuticals Inc
4.44%
Vertex Pharmaceuticals Inc
3.94%
Novartis AG ADR
3.87%
Fate Therapeutics Inc
3.70%
Takeda Pharmaceutical Co Ltd ADR
3.64%
Roche Holding AG ADR
3.63%
Total
Not a recommendation
Possible stop below C or last pivot low.
ARK ETF Trust - ARK Genomic Revolution ETF is an exchange traded fund launched and managed by ARK Investment Management LLC. It invests in public equity markets of global region. The fund invests in stocks of companies operating across diversified sectors. It invests in growth and value stocks of companies across diversified market capitalization. The fund invests in stocks of companies that are deemed socially conscious in their business dealings and directly promote environmental responsibility. The fund employs fundamental and quantitative analysis with bottom-up and top-down stock picking approach to create its portfolio. It benchmarks the performance of its portfolio against the S&P 500 Index and the MSCI World Index. The fund employs internal and external research to create its portfolio. ARK ETF Trust - ARK Genomic Revolution ETF was formed on October 31, 2014 and is domiciled in the United States.
The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified. Benchmark: NASDAQ Health Care GR EUR.
Holdings are an important aspect of an ETF for most. ETFs can be in the same sector yet still have almost totally different holdings at times.
Biotech has pulled back a lot, but biotech is also volatile as a rule.
Top 10 Holdings
Teladoc Health Inc
7.07%
Pacific Biosciences of California Inc
5.24%
Exact Sciences Corp
4.87%
Twist Bioscience Corp
4.55%
Regeneron Pharmaceuticals Inc
4.44%
Vertex Pharmaceuticals Inc
3.94%
Novartis AG ADR
3.87%
Fate Therapeutics Inc
3.70%
Takeda Pharmaceutical Co Ltd ADR
3.64%
Roche Holding AG ADR
3.63%
Total